Prevention and Treatment of Alzheimer's Disease Through CRISPR/Cas Technology
DOI:
https://doi.org/10.54097/bfkfxy78Keywords:
Alzheimer’s disease; CRISPR/Cas technology; treatment.Abstract
Neuronal loss and the stereotyped deposition of misfolded proteins are hallmarks of Alzheimer's disease (AD), A neurodegenerative disease related to age that is common, progressive, and fatal. The formation of amyloid β oligomers may contribute to the pathogenesis of multiple diseases, including the development of tau neurofibrillary tangles and oxidative stress. Between 20% and 40% of persons with AD go on to have severe dementia or pass away within three years. The only things that the current generation of Alzheimer's medications can do are postpone the onset of the illness and make a maximal difference in the lives of those who use them.Early diagnosis, management, and treatment of individuals with neurodegenerative disorders are crucial .But there are currently no relevant treatment options for the accumulation of amyloid beta and neurofibrillary tangles. CRISPR has been widely used in molecular biology research because it is fast, effective, cheap, and easy to operate compared to traditional gene editing methods, and thus has quickly become one of the most popular biological research tools. This article intends to use the gene editing CRISPR technology, which has the advantages of simple design, time period, and low cost, to knock out or edit the genes corresponding to Alzheimer's disease to achieve targeted treatment of this accumulation phenomenon.
Downloads
References
Zhu Ping. The number of patients with Alzheimer’s disease in my country may exceed 40 million in 2050. Experts call for early prevention, early screening, and encouraging continued social investment [N]. 21st Century Business Herald, September 2020 187
World Health Organzation. Dementia. https://www.who.int/zh/news-room/fact-sheets/detail/dementia, 2020.
MCKHANNGM, KNOPMANDS, CHERTKOWH. The diagnosis of dementia due to Alzheimer's disease:recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease [J]. Alzheimers Dement, 2011, 7(3): 263-26
China Dementia and Cognitive Impairment Diagnosis and Treatment Guidelines Writing Group, Du Yifeng, Lu Peiyuan, Ji Yong, et al. 2018 China Dementia and Cognitive Impairment Diagnosis and Treatment Guidelines (5): Diagnosis and Treatment of Mild Cognitive Impairment [J]. Chinese Medical Journal, 2018, 98(17): 1294-1301
Beel A J, Sanders C R. Substrate specificity of γ-secretase and other intramembrane proteases [J]. Cellular & Molecular Life Sciences Cmls, 2008, 65(9): 1311-1134.
Lai Lanmei, Ling Cuixia, Zhang Xiangfei, et al. Research progress on the pathogenesis of Alzheimer's disease [J]. Journal of Shangqiu Normal University, 2018, 34(12): 27-29.
Jinek M, Chylinski K, Fonfara I, et al. A programmable dualRNA-guided DNA endonuclease in adaptive bacterial immunity [J]. Science,2012,337(6096): 816-821
Deltcheva E, Chylinski K, Sharma CM, et al. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III [J]. Nature, 2011,471(7340): 602-607.
Garneau JE, Dupuis Mè, Villion M, et al. The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA [J]. Nature,2010,468(7320): 67-71.
Nishimasu H, Ran FA, Hsu PD, et al. Crystal structure of Cas9 in complex with guide RNA and target DNA [J]. Cell,2014,156(5) : 935-949.
Mali P, Yang L, Esvelt KM, et al. RNA-Guided Human Genome Engineering via Cas9 [J]. Science, 2013, 339 (6121): 823.
Varshney GK, Pei W, LaFave MC, et al. High-throughput gene targeting and phenotyping in zebrafish using CRISPR/Cas9 [J]. Genome Res, 2015, 25(7): 1030-1042
Jiang Zequn, Yang Ye. Application of CRISPR/Cas technology in biomedical research [J]. Pharmaceutical Biotechnology, 2016, 23(05): 412-416.
Bakondi B, Lv W, Lu B, et al. In vivo CRISPR /Cas9 gene editing corrects retinal dystrophy in the S334ter-3 rat model of autosomal dominant retinitis pigmentosa [J]. Mol Ther, 2016, 24 (3): 556-563.
Duan, Y., Ye, T., Qu, Z. et al. Brain-wide Cas9-mediated cleavage of a gene causing familial Alzheimer’s disease alleviates amyloid-related pathologies in mice. Nat Biomed Eng 6, 168–180 (2022).
Henning, N.J., Boike, L., Spradlin, J.N. et al. Deubiquitinase-targeting chimeras for targeted protein stabilization. Nat Chem Biol 18, 412–421 (2022).
Shimizu, T., Fukuda, H., Murayama, S., Izumiyama, N. & Shirasawa, T. Isoaspartate formation at position 23 of amyloid beta peptide enhanced fibril formation and deposited onto senile plaques and vascular amyloids in Alzheimer’s disease. J. Neurosci. Res. 70, 451–461 (2002).
Kaneko, I., Morimoto, K. & Kubo, T. Drastic neuronal loss in vivo by β-amyloid racemized at Ser26 residue: Conversion of non-toxic [D-Ser26] β-amyloid 1–40 to toxic and proteinase-resistant fragments. Neuroscience 104, 1003–1011 (2001).
Shimizu, T., Watanabe, A., Ogawara, M., Mori, H. & Shirasawa, T. Isoaspartate formation and neurodegeneration in Alzheimer’s disease. Arch Biochem. Biophys. 381, 225–234 (2000).
Fisher, G. et al. Free D- and L-amino acids in ventricular cerebrospinal fluid from Alzheimer and normal subjects. Amino Acids 15, 263–269 (1998).
Roher, A. E. et al. Structural alterations in the peptide backbone of β-amyloid core protein may account for its deposition and stability in Alzheimer’s disease. J. Biol. Chem. 268, 3072–3083 (1993).
Miles, L., Crespi, G., Doughty, L. et al. Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation. Sci Rep 3, 1302 (2013).
Readel, E.R., Patel, A., Putman, J.I. et al. Antibody binding of amyloid beta peptide epimers/isomers and ramifications for immunotherapies and drug development. Sci Rep 13, 12387 (2023)
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
